发明Methods of treating cancer

pdf收藏

著录项目

申请号 US20070853700 申请日 2007年09月11日 最早公开日 2008年05月22日 所属国家/地区 美国
公开号及公开日 US2008119562A1   2008年05月22日
US7732490B2   2010年06月08日
授权日 2010年06月08日 说明书附图
申请人 RICHON VICTORIA M (美国)  
CHIAO JUDY H (美国)  
KELLY WILLIAM KEVIN (美国)  
MILLER THOMAS A (美国)  
发明人 RICHON VICTORIA M   CHIAO JUDY H   KELLY WILLIAM KEVIN   MILLER THOMAS A  
优先权 US20020361759P   20020304US20030379149   20030304US20070853700   20070911
专利分类号 A01N37/28   A61K9/48   A61K31/13   A61K31/16   A61K31/165   A61K31/19   A61K31/426   A61K31/44   A61K31/4402   A61K31/4406   A61K31/4409   A61K31/445   A61K31/4706   A61K31/4709   A61K38/12   A61K47/12   A61K47/38   A61P35/00   A61P43/00   C07C259/04   G01N33/579   A61K31/164  
代理机构 代理人

名称及摘要

方法,用于诱导末端分化
本发明提供方法,用于选择性地诱导末端分化,细胞生长停止和/或凋肿瘤单元,和/或抑制组蛋白去乙酰化酶( HDAC )通过施用药品成分,包括有效的 HDAC 抑制剂。 口腔生物可用性活性化合物中药品成分本发明是高。 此外,本药品成分出乎意料地引起高,治疗有效血液水平活性化合物上持续时间时间。 本发明进一步提供安全,日剂量方案这些药品成分,其容易遵循,以及,其导致治疗有效量 HDAC 抑制剂活体内。
Methods of treating cancer
The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.

同族及引用

同族专利 (45) 引用其他专利(201) 被其他专利引用(94)

CA2478094C METHODS OF INDUCING TERMINAL DIFFERENTIATION
CA2632078C METHODS OF INDUCING TERMINAL DIFFERENTIATION
CA2671976C METHODS OF INDUCING TERMINAL DIFFERENTIATION
WO03075839A3 METHODS OF INDUCING TERMINAL DIFFERENTIATION
AU2003213684C1 Methods of inducing terminal differentiation
US2004072735A1 Methods of inducing terminal differentiation
US2004127523A1 Methods of treating cancer with HDAC inhibitors
US7399787B2 Methods of treating cancer with HDAC inhibitors
NO332749B1 Progress Mate by induction of terminal differentiation
NO329984B1 composition comprising crystalline suberoylanilid hydroxamic acid (SAHA) and processes for their preparation feed
EP1487426B1 METHODS OF INDUCING TERMINAL DIFFERENTIATION
BR0308250A 【Title of corresponding document:CN103393630A】 Method of inducing terminal differentiation
PL372239A1 METHODS OF INDUCING TERMINAL DIFFERENTIATION
MXPA04008577A METHODS OF INDUCING TERMINAL DIFFERENTIATION.
RU2320331C2 METHOD OF INDUCTION OF TERMINAL DIFFERENTIATION
JP4732693B2 【Title of corresponding document:CN103393630A】 Method of inducing terminal differentiation
IL163909D0 Methods of inducing terminal differentiation
CN1720034A 诱导末期分化的方法
ZA200407942B Methods of including terminal differentiation
KR100868813B1 Methods of inducing terminal differentiation
in5143DELNP2007A METHODS OF INDUCING TERMINAL DIFFERENTIATION
ZA200601757B Methods of inducing terminal differentiation
NZ535578A Methods of inducing terminal differentiation
KR100892016B1 Methods of inducing terminal differentiation
US2008114069A1 Methods of inducing terminal differentiation
US7732490B2 Methods of treating cancer
CN101259120B 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途
RU2394022C2 METHOD OF INDUCING TERMINAL DIFFERENTIATION
NZ550185A Methods of inducing terminal differentiation Methods of inducing terminal differentiation
IN236771A1 "a pharmaceutical composition for oral administration"
EP2082737B1 Methods of inducing terminal differentiation
NZ567758A Methods of inducing terminal differentiation using suberoylanilide hydrozmic acid (SAHA)
IL197582A Pharmaceutical compositions comprising a crystalline form of suberoylanilide hydroxamic acid (saha) and methods for saha preparation
JP5586896B2 METHOD FOR INDUCING TERMINAL DIFFERENTIATION
JP5675071B2 METHOD OF INDUCING TERMINAL DIFFERENTIATION
US8067472B2 Methods of treating Hodgkin's and non-Hodgkin's lymphoma
EP2266552A3 Methods of inducing terminal differentiation
IL163909A PHARMACEUTICAL COMPOSITIONS COMPRISING A SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) OR A PHARMACEUTICALLY ACCEPTABLE SALT OR HYDRATE AND USES OF SAID SAHA OR PHARMACEUTCALLY ACCEPTABLE SALT OR HYDRATE THEREOF
EP2322160A1 Methods of inducing terminal differentiation
RU2530648C2 METHOD OF FINAL DIFFERENTIATION INDUCTION
US2012041067A1 Methods of Inducing Terminal Differentiation
HK1072362A1 METHODS OF INDUCING TERMINAL DIFFERENTIATION
CN103393630A 诱导末期分化的方法
JP2014237669A METHOD OF INDUCING FINAL DIFFERENTIATION
ES2532607T3 【Title of corresponding document:EP2082737A2】 Methods of inducing terminal differentiation
Formulations of suberoylanilide hydroxamic acid and methods for producing same
Formulations of suberoylanilide hydroxamic acid and methods for producing same
Formulations of suberoylanilide hydroxamic acid and methods for producing same
HDAC inhibitors to treat Charcot-Marie-Tooth disease
伏立诺他在制备治疗自身免疫及炎症性疾病药物方面的应用
N-烃酰基环内酰胺衍生物的一锅合成方法
伏立诺他用于制备免疫调节药物的应用
一种制备抗癌药物伏立诺他的方法
METHOD OF TREATING TRX MEDIATED DISEASES
Use of SAHA for treating mesothelioma
METHOD TO ENHANCE THE BONE FORMATION ACTIVITY OF BMP BY RUNX2 ACETYLATION
METHODS FOR TREATMENT OF HEMORRHAGIC SHOCK AND RELATED DISORDERS
HYBRID MOLECULES HAVING MIXED VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITORY PROPERTIES
Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
NEW USE OF HISTONE DEACETYLASE INHIBITORS IN CHANGING MRJP3 PROTEIN IN ROYAL JELLY
Formulations of suberoylanilide hydroxamic acid and methods for producing same
Use of SAHA for treating mesothelioma
Formulations of suberoylanilide hydroxamic acid and methods for producing same
【Title of corresponding document:CA2520611A1】 HYDROXAMIC ACID COMPOUNDS AND METHODS OF USE THEREOF
【Title of corresponding document:CN101001851B】 Hydroxyamide compounds having activity as inhibitors of histone deacetylase (HDAC)
【Title of corresponding document:CA2580367C】 FORMULATIONS OF SUBEROYLANILIDE HYDROXAMIC ACID AND METHODS FOR PRODUCING SAME
【Title of corresponding document:CN101299921A】 Methods of treating cancers with saha, carboplatin
【Title of corresponding document:CN101300015A】 Method of using SAHA and Erlotinib for treating cancer
FORMULATION OF SUBEROYLANILIDE HYDROXAMIC ACID AND METHOD FOR PRODUCING SAME
METHOD OF INDUCING FINAL DIFFERENTIATION
Formulations of suberoylanilide hydroxamic acid and methods for producing same
ANTITUMOUR COMPOUNDS
1,8-辛二醯基苯胺羟胺酸(suberoylanilide hydroxamic acid)之调配物及其制配方法
Methods of inducing terminal differentiation
Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer
Polymorphs of suberoylanilide hydroxamic acid
Methods of treating cancer with HDAC inhibitors
Electrical power jack
Methods of treating mesothelioma with suberoylanilide hydroxamic acid
Methods of treating cancer with HDAC inhibitors
Methods of treating cancer with HDAC inhibitors
Histone deacetylase inhibitors
Histone deacetylase inhibitors
Methods of treating cancer with hdac inhibitors
Histone deacetylase inhibitors
Histone deacetylase inhibitors
Histone deacetylases, and uses related thereto
Method of treating TRX mediated diseases
Method of treating TRX mediated diseases
Treatment of cancer of the brain using histone deacetylase inhibitors
Histone deacetylase inhibitors
Methods of Treating Cancers with SAHA, Carboplatin, and Paclitaxel and Other Combination Therapies
Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
Process for the preparation of esomeprazole non-salt form
Histone deacetylase inhibitors
Treatment of protein degradation disorders
Methods of treating cancer with HDAC inhibitors
Histone deacetylase inhibitors
Methods of treating cancer with HDAC inhibitors
Methods of using SAHA and Erlotinib for treating cancer
Methods of using SAHA and Bortezomib for treating cancer
Metabolite derivatives of the HDAC inhibitor FK228
Formulations of suberoylanilide hydroxamic acid and methods for producing the same
Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents
Pharmaceutical Compounds
Pharmaceutical Compounds
Combination Therapies Using Hdac Inhibitors
Method for use of an electrochemical sensor and electrodes forming said sensor
Pharmaceutical formulations of HDAC inhibitors
Enzyme and Receptor Modulation
Histone deacetylase inhibitors
Therapeutic Combination
Histone deacetylase inhibitors
Bifunctional histone deacetylase inhibitors
Treatment of Ras-expressing tumors
Histone deacetylase and tubulin deacetylase inhibitors
Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
Pharmaceutical compositions of HDAC inhibitors and chelatable metal compounds, and metal-HDAC inhibitors chelate complexes
METHODS OF USING SAHA AND BORTEZOMIB FOR TREATING MULTIPLE MYELOMA
ROMIDEPSIN-BASED TREATMENTS FOR CANCER
HISTONE DEACETYLASE INHIBITORS
Hydroxamic acid compounds and methods of use thereof
Deacetylase inhibitor therapy
Methods of treating cancer
Dioxanes and uses thereof
HISTONE DEACETYLASE INHIBITORS
HISTONE DEACETYLASE INHIBITORS
Histone deacetylase inhibitors
HISTONE DEACETYLASE INHIBITORS
HISTONE DEACETYLASE INHIBITORS
Preparation of romidepsin
Methods of treating cancer with HDAC inhibitors
Polymorphs of suberoylanilide hydroxamic acid
Methods of treating cancer with HDAC inhibitors
Methods of inducing terminal differentiation
Polymorphs of suberoylanilide hydroxamic acid
Polymorphs of suberoylanilide hydroxamic acid
Method of using SAHA and Erlotinib for treating cancer
Methods of using saha and bortezomib for treating cancer
Method of treating cancers with SAHA and Pemetrexed
HISTONE DEACETYLASES, AND USES RELATED THERETO
Methods of treating cancer with HDAC inhibitors
Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer
USE OF HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM METASTASES
Methods of synthesis of certain hydroxamic acid compounds
Nucleic acids encoding class II human histone deacetylases, and uses related thereto
Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
PREPARATION OF ROMIDEPSIN
Hydroxamates as inhibitors of histone deacetylase
Polymorphs of suberoylanilide hydroxamic acid
Methods of Treatment Employing Prolonged Continuous Infusion of Belinostat
Deacetylase inhibitors and uses thereof
Process for the preparation of vorinostat
Crystalline vorinostat form VI
Methods for identifying patients who will respond well to cancer treatment
Formulations of suberoylanilide hydroxamic acid and methods for producing same
Formulations of suberoylanilide hydroxamic acid and methods for producing same
METHODS AND COMPOSITIONS FOR REGULATING HDAC6 ACTIVITY
Combinations of pyrazole kinase inhibitors
Methods of treating Hodgkin's and non-Hodgkin's lymphoma
Benzamide derivatives useful as histone deacetylase inhibitors
SYSTEMS AND METHODS FOR IMPROVING BIOMARKER AVAILABILITY
METHODS OF IDENTIFYING BIOMARKERS FOR CANCER
Systems and methods of screening biomarkers in bodily fluids
METHODS OF DETERMINING STABILIZATION COMPOUNDS FOR PREDICTIVE BIOMARKERS
Methods for determining the efficiency of a therapeutic
SYSTEMS AND METHODS FOR DETERMINING THERAPEUTIC POTENTIAL
BIOMARKER STABILIZING AGENTS
SAMPLE CONTAINER FOR BIOMARKER MAINTENANCE
DEVICES AND SYSTEMS FOR BIOMARKER DETECTION
TRANSPORT CONTAINER FOR STABILIZED LIQUID SAMPLES
DEVICES AND SYSTEMS FOR BIOMARKER DETECTION
DEVICES FOR COLLECTION AND STABILIZATION OF BIOMARKERS IN LIQUID SAMPLES
DEVICES FOR COLLECTION AND STABILIZATION OF BIOMARKERS IN LIQUID SAMPLES
RINSE COMPOSITION FOR THE STABILIZATION OF DIAGNOSTIC BIOMARKERS
DRINK MIXTURE FOR THE STABILIZATION OF DIAGNOSTIC BIOMARKERS
SYSTEMS AND METHODS FOR DETECTING INSULIN RESISTANCE BIOMARKERS
Systems and methods for biomarker analysis
SYSTEMS AND METHODS FOR THE INHIBITION OF GALACTOSE OXIDASE
SYSTEMS FOR ANALYZING STABILIZED BIOMARKERS
SYSTEMS AND METHODS OF ANALYZING BIOMARKER LEVELS
Systems and methods for hemoglobin analysis
SYSTEMS AND METHODS FOR DIAGNOSING CANCER
SYSTEMS AND METHODS FOR DETERMINING FOOD ALLERGIES
Systems and methods for the detection of biomarkers
SYSTEMS AND METHODS FOR DETERMINING CARDIAC CONDITIONS
Systems and methods for the detection of biomarkers
SYSTEMS AND METHODS FOR IDENTIFYING ALLERGIES
SYSTEMS AND METHODS FOR DIAGNOSING BACTERIAL INFECTIONS
SYSTEMS AND METHODS FOR DIAGNOSING VIRAL INFECTIONS
SYSTEMS AND METHODS FOR DIAGNOSING FUNGAL INFECTIONS
SYSTEMS AND METHODS FOR DETECTING DRUG USE
SYSTEMS AND METHODS FOR DIAGNOSING PARASITE INFECTIONS
SYSTEMS AND METHODS FOR FERTILITY ANALYSIS
SYSTEMS AND METHODS FOR DETECTING PREGNANCY
SYSTEMS AND METHODS FOR DETERMINING CALCIUM LEVELS
Class- and isoform-specific HDAC inhibitors and uses thereof
Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
Treatment Of Neurodegenerative Diseases And Cancer Of The Brain Using Histone Deacetylase Inhibitors
Histone deacetylases, and uses related thereto
Methods of reducing symptoms in subjects using single dosage forms with tapering release rates
4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors
Histone deacetylases, and uses related thereto
Histone deacetylases, and uses related thereto
Therapy for MLL-rearranged leukemia
Methods of Inducing Terminal Differentiation
3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators
Class II human histone deacetylases, and uses related thereto
Bifunctional histone deacetylase inhibitors
Histone deacetylases, and uses related thereto
Deacetylase inhibitors and uses thereof
Class II human histone deacetylases, and uses related thereto
Resistance biomarkers for HDAC inhibitors
Inhibition of drug resistant cancer cells
Class- and isoform-specific HDAC inhibitors and uses thereof
3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators
Romidepsin solid forms and uses thereof
HDAC inhibitors to treat charcot-marie-tooth disease
Pharmaceutical formulations of HDAC inhibitors
Histone deacetylase (HDAC) inhibitors for the treatment of cancer
Process for the preparation of vorinostat
Deacetylase inhibitor therapy
Romidepsin solid forms and uses thereof
Treatment of protein degradation disorders
Histone deacetylase inhibitors
Romidepsin solid forms and uses thereof
Romidepsin formulations and uses thereof
Romidepsin formulations and uses thereof
Romidepsin formulations and uses thereof
Romidepsin formulations and uses thereof
USE OF A HISTONE DEACETYLASE INHIBITOR FOR TREATING MUSCULAR DYSTROPHIES
METHOD OF TREATING CANCER WITH HDAC INHIBITORS
PHARMACEUTICAL COMPOUNDS
THERAPEUTIC COMBINATION OF HAMLET AND A HDAC INHIBITOR TO TREAT CANCER
HISTONE DEACETYLASE INHIBITORS
FORMULATIONS OF SUBEROYLANILIDE HYDROXAMIC ACID AND METHODS FOR PRODUCING SAME
FORMULATIONS OF SUBEROYLANILIDE HYDROXAMIC ACID AND METHODS FOR PRODUCING SAME
MODULATION OF NEUROGENESIS BY HDAC INHIBITION
METHODS OF USING SAHA AND ERLOTINIB FOR TREATING CANCER
BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS
Histone Deacetylase Inhibitors
CANCER THERAPY WITH COMBINATIONS OF FTS WITH HDAC INHIBITORS
HDAC INHIBITORS TO TREAT CHARCOT-MARIE-TOOTH DISEASE
DEVICES, SYSTEMS, AND METHODS FOR BIOMARKER STABILIZATION
DEVICES AND WASHES FOR BIOMARKER STABILIZATION
METHODS OF TREATING CANCER AND PREVENTING CANCER DRUG RESISTANCE
SUBSTITUTED BENZIMIDAZOLONES
Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound
System of magnet with annular air-gap
PROCESS FOR PREPARING NOVEL SUBSTITUTED PROPANOL*2**DERIVATIVE AND ITS NICOTIC ACID ESTER
PRODUCTION OF DICARBOXYLIC ACID DIANILIDE
【Title of corresponding document:us5932616A】 Potent inducers of terminal differentiation and methods of use thereof
EXAMINATION OF METASTASIS OF B CELLULOUS LYMPHOMA TO BONE MARROW
【Title of corresponding document:us7126001B2】 Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
METHOD OF INDUCING TERMINAL DIFFERENTIATION
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
Use of trichostatin compounds for treating tumor cells
NOVEL POTENT INDUCERS OF THERMAL DIFFERENTIATION AND METHOD OF USE THEREOF
Potent inducers of terminal differentiation and methods of use thereof
Potent inducers of terminal differentiation and methods of use thereof
Potent inducers of terminal differentiation and methods of use thereof
Potent inducers of terminal differentiation and method of use thereof
Potent inducers of terminal differentiation and method of use thereof
Methods for prevention of cancer using phenylacetic acids and derivatives thereof
Potent inducers of terminal differentiation and method of use thereof
Compositions and administration of compositions for the treatment of blood disorders
Method of treating mammals
Transcription therapy for cancers
Potent inducers of terminal differentiation and methods of use thereof
Uses of hydroxy and ether-containing oxyalkylene esters for treating metabolic conditions
Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
Wound treatment method and device with combination of ultrasound and laser energy
Potent inducers of terminal differentiation and methods of use thereof
Chemotherapy of cancer with actyldinaline in combination with gemcitabine capecitabine or cisplatin
Histone deacetylase inhibitors
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
Compositions and administration of compositions for the treatment of blood disorders
Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
Method of treating autoimmune diseases
Polynucleotides encoding human histone deacetylase HDAC9c
Method of treating autoimmune diseases
Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents
Method of treating TRX mediated diseases
Methods of inducing terminal differentiation
Carbamic acid compounds comprising an ether linkage as HDAC inhibitors
Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer
Polymorphs of suberoylanilide hydroxamic acid
Methods of treating cancer with HDAC inhibitors
Methods of treating mesothelioma with suberoylanilide hydroxamic acid
Methods of treating cancer with HDAC inhibitors
Methods of treating cancer with HDAC inhibitors
Treatment of lung cells with histone deacetylase inhibitors
Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
Methods of treating cancer with hdac inhibitors
Combination methods of treating cancer
Hydroxamic acid compounds and methods of use thereof
Treatment of cancer of the brain using histone deacetylase inhibitors
Methods of treating cancer with HDAC inhibitors
Methods of treating cancer with HDAC inhibitors
Method of treating cancers with SAHA and pemetrexed
Methods of using SAHA and Bortezomib for treating cancer
Combination methods fo saha and targretin for treating cancer
Methods of treating cancer
Methods of treating cancer with HDAC inhibitors
Polymorphs of suberoylanilide hydroxamic acid
Methods of treating cancer with HDAC inhibitors
Polymorphs of suberoylanilide hydroxamic acid
Polymorphs of suberoylanilide hydroxamic acid
Method of using SAHA and Erlotinib for treating cancer
Methods of treating cancer with HDAC inhibitors
Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer
Polymorphs of suberoylanilide hydroxamic acid
Methods of treating Hodgkin's and non-Hodgkin's lymphoma
NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHODS OF USE THEREOF
HISTONE DEACETYLASE AS TARGET FOR ANTIPROTOZOAL AGENTS
HYDROXAMIC ACID COMPOUNDS HAVING ANTICANCER AND ANTI-PARASITIC PROPERTIES
UNSATURATED OXYALKYLENE ESTERS AND USES THEREOF
OXYALKYLENE PHOSPHATE COMPOUNDS AND USES THEREOF
COMPOUNDS USEFUL FOR THE MODULATION OF PROCESSES MEDIATED BY NUCLEAR HORMONE RECEPTORS, METHODS FOR THE IDENTIFICATION AND USE OF SUCH COMPOUNDS
INHIBITOR OF HISTONE DEACETYLASE
CYCLIC TETRAPEPTIDE AND THEIR USE AS HISTONE DEACETYLASE INHIBITOR
TREATMENT OF FOLLICULAR LYMPHOMAS USING INHIBITORS OF THE LYMPHOTOXIN (LT) PATHWAY
BENZAMIDE FORMULATION WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY
INHIBITION OF HISTONE DEACETYLASE
INHIBITORS OF HISTONE DEACETYLASE
CANNULA WITH COUPLING INTERFACE
NOVEL CLASS OF CYTODIFFERENTIATING AGENTS AND HISTONE DEACETYLASE INHIBITORS, AND METHODS OF USE THEREOF
METHODS FOR USING 22045, A HUMAN CYCLIC NUCLEOTIDE PHOSPHODIESTERASE
HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS
TETRALONE DERIVATIVES AS ANTITUMOR AGENTS
CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS
INHIBITORS OF HISTONE DEACETYLASE
METHODS OF TREATING CUTANEOUS AND PERIPHERAL T-CELL LYMPHOMA BY A HISTONE DEACETYLASE INHIBITOR
METHOD OF TREATING AUTOIMMUNE DISEASES
HISTONE DEACETYLASE ENZYME-INHIBITING DERIVATIVES OF HYDROXAMIC ACID AS NEW CYTOKINE SYNTHESIS-INHIBITING ANTI-INFLAMMATORY DRUGS
COMPOSITIONS AND METHODS FOR REESTABLISHING GENE TRANSCRIPTION THROUGH INHIBITION OF DNA METHYLATION AND HISTONE DEACETYLASE
METHODS OF INDUCING TERMINAL DIFFERENTIATION
COMBINATION METHODS OF SAHA AND TARGRETIN FOR TREATING CANCER
METHODS OF TREATING CANCERS WITH SAHA, CARBOPLATIN, AND PACLITAXEL AND OTHER COMBINATION THERAPIES

法律状态历史( 到官方网站查询 )

2007年09月11日 us_a.pe (更多信息: Preliminary Amendment , A.PE)
2007年09月11日 us_scan (更多信息: IFW Scan & PACR Auto Security Review , SCAN)
2007年09月11日 us_iexx (更多信息: Initial Exam Team nn , IEXX)
2007年09月12日 us_l198 (更多信息: Referred to Level 2 (LARS) by OIPE CSR , L198)
2007年11月09日 us_a.pe (更多信息: Preliminary Amendment , A.PE)
2007年11月16日 us_l128 (更多信息: Cleared by L&R (LARS) , L128)
2007年11月30日 us_idsc (更多信息: Information Disclosure Statement considered , IDSC)
2007年11月30日 us_rcap (更多信息: Reference capture on IDS , RCAP)
2007年11月30日 us_m844 (更多信息: Information Disclosure Statement (IDS) Filed , M844)
2007年11月30日 us_wids (更多信息: Information Disclosure Statement (IDS) Filed , WIDS)
2007年12月11日 us_flrcpt.o (更多信息: Filing Receipt , FLRCPT.O)
2008年01月08日 us_m844 (更多信息: Information Disclosure Statement (IDS) Filed , M844)
2008年01月08日 us_idsc (更多信息: Information Disclosure Statement considered , IDSC)
2008年01月08日 us_wids (更多信息: Information Disclosure Statement (IDS) Filed , WIDS)
2008年01月28日 us_as 转让(新专利权人: ATON PHARMA,INC. (A SUBSIDIARY OF MERCK & CO.,IN
更多信息: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHIAO,JUDY H.;MILLER,THOMAS A.;RICHON,VICTORIA M.;REEL/FRAME:020424/0280;SIGNING DATES FROM 20060809 TO 20060821)
2008年01月28日 us_as 转让(新专利权人: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH,NEW
更多信息: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RICHON,VICTORIA M.;KELLY,W. KEVIN;REEL/FRAME:020424/0530;SIGNING DATES FROM 20060809 TO 20061023)
2008年01月28日 us_as 转让(新专利权人: MERCK HDAC RESEARCH,LLC,MASSACHUSETTS
更多信息: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ATON PHARMA,INC.;REEL/FRAME:020424/0613
生效日期: 20060828)
2008年01月28日 us_as 转让(新专利权人: ATON PHARMA,INC. (A SUBSIDIARY OF MERCK & CO.,IN
更多信息: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHIAO,JUDY H.;MILLER,THOMAS A.;RICHON,VICTORIA M.;SIGNING DATES FROM 20060809 TO 20060821;REEL/FRAME:020424/0280)
2008年01月28日 us_as 转让(新专利权人: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH,NEW
更多信息: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RICHON,VICTORIA M.;KELLY,W. KEVIN;SIGNING DATES FROM 20060809 TO 20061023;REEL/FRAME:020424/0530)
2008年01月28日 us_a.pe (更多信息: Preliminary Amendment , A.PE)
2008年01月28日 us_c614 (更多信息: New or Additional Drawing Filed , C614)
2008年01月28日 us_addflfee (更多信息: Additional Application Filing Fees , ADDFLFEE)
2008年01月28日 us_corrdrw (更多信息: Applicant has submitted new drawings to correct Corrected Papers problems , CORRDRW)
2008年02月13日 us_pgpc (更多信息: Sent to Classification Contractor , PGPC)
2008年02月13日 us_flrcpt.u (更多信息: Filing Receipt - Updated , FLRCPT.U)
2008年02月13日 us_comp (更多信息: Application Is Now Complete , COMP)
2008年03月02日 us_oipe (更多信息: Application Dispatched from OIPE , OIPE)
2008年04月07日 us_a.pe (更多信息: Preliminary Amendment , A.PE)
2008年04月09日 us_m844 (更多信息: Information Disclosure Statement (IDS) Filed , M844)
2008年04月09日 us_idsc (更多信息: Information Disclosure Statement considered , IDSC)
2008年04月09日 us_wids (更多信息: Information Disclosure Statement (IDS) Filed , WIDS)
2008年04月30日 us_dock (更多信息: Case Docketed to Examiner in GAU , DOCK)
2008年05月12日 us_tsscomp (更多信息: IFW TSS Processing by Tech Center Complete , TSSCOMP)
2008年05月22日 us_pg-issue (更多信息: PG-Pub Issue Notification , PG-ISSUE)
2008年07月21日 us_ctnf (更多信息: Non-Final Rejection , CTNF)
2008年07月28日 us_mctnf (更多信息: Mail Non-Final Rejection , MCTNF)
2008年08月29日 us_as 转让(新专利权人: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH,NEW
更多信息: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MERCK HDAC RESEARCH,LLC (A SUBSIDIARY OF MERCK & CO.,INC.);REEL/FRAME:021461/0358
生效日期: 20080827)
2008年11月06日 us_idsc (更多信息: Information Disclosure Statement considered , IDSC)
2008年11月06日 us_a... (更多信息: Response after Non-Final Action , A...)
2008年11月06日 us_xt/g (更多信息: Request for Extension of Time - Granted , XT/G)
2008年11月06日 us_rcap (更多信息: Reference capture on IDS , RCAP)
2008年11月06日 us_m844 (更多信息: Information Disclosure Statement (IDS) Filed , M844)
2008年11月06日 us_wids (更多信息: Information Disclosure Statement (IDS) Filed , WIDS)
2008年11月19日 us_fwdx (更多信息: Date Forwarded to Examiner , FWDX)
2009年02月02日 us_ctnf (更多信息: Non-Final Rejection , CTNF)
2009年02月04日 us_idsc (更多信息: Information Disclosure Statement considered , IDSC)
2009年02月04日 us_rcap (更多信息: Reference capture on IDS , RCAP)
2009年02月04日 us_m844 (更多信息: Information Disclosure Statement (IDS) Filed , M844)
2009年02月04日 us_wids (更多信息: Information Disclosure Statement (IDS) Filed , WIDS)
2009年02月05日 us_mctnf (更多信息: Mail Non-Final Rejection , MCTNF)
2009年05月05日 us_a... (更多信息: Response after Non-Final Action , A...)
2009年05月22日 us_idsc (更多信息: Information Disclosure Statement considered , IDSC)
2009年05月22日 us_rcap (更多信息: Reference capture on IDS , RCAP)
2009年05月22日 us_m844 (更多信息: Information Disclosure Statement (IDS) Filed , M844)
2009年05月22日 us_wids (更多信息: Information Disclosure Statement (IDS) Filed , WIDS)
2009年06月03日 us_fwdx (更多信息: Date Forwarded to Examiner , FWDX)
2009年07月29日 us_rcap (更多信息: Reference capture on IDS , RCAP)
2009年07月29日 us_m844 (更多信息: Information Disclosure Statement (IDS) Filed , M844)
2009年07月29日 us_idsc (更多信息: Information Disclosure Statement considered , IDSC)
2009年07月29日 us_wids (更多信息: Information Disclosure Statement (IDS) Filed , WIDS)
2009年08月18日 us_idsc (更多信息: Information Disclosure Statement considered , IDSC)
2009年08月18日 us_m844 (更多信息: Information Disclosure Statement (IDS) Filed , M844)
2009年08月18日 us_wids (更多信息: Information Disclosure Statement (IDS) Filed , WIDS)
2009年08月18日 us_ctnf (更多信息: Non-Final Rejection , CTNF)
2009年08月20日 us_mctnf (更多信息: Mail Non-Final Rejection , MCTNF)
2009年11月23日 us_as 转让(新专利权人: MERCK HDAC RESEARCH,LLC,MASSACHUSETTS
更多信息: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH;REEL/FRAME:023559/0236
生效日期: 20091123)
2009年11月23日 us_dist (更多信息: Terminal Disclaimer Filed , DIST)
2009年11月23日 us_a... (更多信息: Response after Non-Final Action , A...)
2009年11月23日 us_xt/g (更多信息: Request for Extension of Time - Granted , XT/G)
2009年12月06日 us_fwdx (更多信息: Date Forwarded to Examiner , FWDX)
2010年01月27日 us_n/=. (更多信息: Notice of Allowance Data Verification Completed , N/=.)
2010年01月27日 us_dock (更多信息: Case Docketed to Examiner in GAU , DOCK)
2010年02月01日 us_mn/=. (更多信息: Mail Notice of Allowance , MN/=.)
2010年04月23日 us_n084 (更多信息: Issue Fee Payment Verified , N084)
2010年04月23日 us_ifee (更多信息: Issue Fee Payment Received , IFEE)
2010年05月06日 us_pils (更多信息: Application Is Considered Ready for Issue , PILS)
2010年05月07日 us_d1935 (更多信息: Dispatch to FDC , D1935)
2010年05月19日 us_wpir (更多信息: Issue Notification Mailed , WPIR)
2010年06月08日 us_pgm/ (更多信息: Recordation of Patent Grant Mailed , PGM/)
2010年06月08日 us_ptac (更多信息: Patent Issue Date Used in PTA Calculation , PTAC)
2010年08月17日 us_n423 (更多信息: Post Issue Communication - Certificate of Correction , N423)
2010年08月23日 us_as 转让(新专利权人: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH,NEW
更多信息: CHANGE OF ADDRESS OF ASSIGNEE;ASSIGNOR:MERCK HDAC RESEARCH,LLC (A SUBSIDIARY OF MERCK & CO.,INC.);REEL/FRAME:024870/0864
生效日期: 20080827)
2010年09月07日 us_cc 更正的证书()
2011年06月14日 us_n423 (更多信息: Post Issue Communication - Certificate of Correction , N423)
2011年07月05日 us_cc 更正的证书()
2012年03月28日 us_as 转让(新专利权人: NATIONAL INSTITUTES OF HEALTH (NIH),U.S. DEPT. OF
更多信息: CONFIRMATORY LICENSE;ASSIGNOR:SLOAN-KETTERING INSTITUTE FOR CANCER RES;REEL/FRAME:027943/0092
生效日期: 20120326)
2013年05月17日 us_n423 (更多信息: Post Issue Communication - Certificate of Correction , N423)
2013年06月18日 us_cc 更正的证书()
2013年12月09日 us_fpay 缴费(付费年限: 4)
2016年08月05日 us_n423 (更多信息: Post Issue Communication - Certificate of Correction , N423)
2016年08月30日 us_cc 更正的证书()
2017年11月20日 us_mafp (付费年限: 8)

更新记录

2014年06月20日